| Literature DB >> 29987351 |
Akira Yamamoto1, Yusuke Meguri1,2, Akiko Fukuda1,3, Yui Kambara1, Tomohiro Urata1, Taiga Kuroi1, Taro Masunari1, Nobuo Sezaki1, Toru Kiguchi4.
Abstract
Entities:
Mesh:
Substances:
Year: 2018 PMID: 29987351 PMCID: PMC6342889 DOI: 10.1007/s00277-018-3430-6
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673
Fig. 1The progress of treatment, with symptoms and neuroimages. a The blood concentrations of CsA (ng/mL) and the times of prescription to treat severe AA. b Blood pressure (circles: SBP; squares: DBP; mmHg) and symptoms over time (stripes: thunderclap headaches from day 5 to 11; polka-dots: visual disorders from day 13 to 15). c (a.) The MRI DWI map (left) and the MRI ADC map (right) reveal fresh cerebral infarction of the left occipital lobe (arrows) on day 14 after treatment commenced. (b.) MRA of the arterial circle of Willis reveals segmental vasoconstrictions of the basilar artery, the anterior and posterior communicating arteries, and the anterior and middle cerebral arteries, on day 14 after treatment commenced. (c.) MRA of the arterial circle of Willis reveals diffuse improvement of vasoconstriction on day 29 after treatment commenced. CsA cyclosporine A, AA aplastic anemia, ATG anti-thymocyte globulin, mPSL methylprednisolone, SBP systolic blood pressure, DBP diastolic blood pressure, MRI magnetic resonance imaging, DWI diffusion-weighted imaging, MRA magnetic resonance angiography, ADC apparent diffusion coefficient